-
Jefferies Maintains Buy on Amarin
Friday, June 3, 2011 - 8:15am | 109Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "A competitor has raised questions raised over the validity of the statistical analyses used in the MARINE and ANCHOR studies, but for reasons we outline below, we remain...
-
Jefferies Assumes Coverage of Avanir Pharmaceuticals
Friday, June 3, 2011 - 7:47am | 75Jefferies is assuming coverage of Avanir Pharmaceuticals (NASDAQ: AVNR) with a $3.50 price target and a Hold rating. “AVNR markets Nuedexta, a low-dose combination of dextromethorphan and quinidine, for pseudobulbar affect, a disorder of laughing or crying that can accompany neurological disease...
-
JP Morgan Upgrades Forest Laboratories To Overweight, PT Raised To $41
Friday, June 3, 2011 - 6:56am | 40JP Morgan has upgraded Forest Laboratories (NYSE: FRX) from Neutral to Overweight and has raised the price target from $38 to $41 as a favorable risk/reward profile is being witnessed for the stock.
-
DURECT Announces Resignation of Chief Medical Officer
Thursday, June 2, 2011 - 4:15pm | 47DURECT Corporation (Nasdaq: DRRX) announced today that Dr. Joseph Stauffer, Chief Medical Officer and Executive Vice President, Corporate Strategy has resigned effective June 21, 2011 to pursue other opportunities. Dr. Stauffer and DURECT have entered into a consulting agreement through December...
-
Clovis Oncology, Inc. Receives License for Worldwide Development and Commercialization Rights to Pfizer's Oral and IV PARP Inhibitor PF-01367338
Thursday, June 2, 2011 - 3:24pm | 287Clovis Oncology announced today an agreement with Pfizer Inc. (NYSE: PFE) for the development and commercialization of Pfizer's oral and IV Poly (ADP-ribose) polymerase inhibitor, PF-01367338, currently in Phase 1/2 development for solid tumors. PF-01367338 is a novel, orally active, small...
-
My Top 20 Defensive Stock Plays
Thursday, June 2, 2011 - 2:24pm | 244Here is my list of top defensive plays in this highly volatile market. If you're looking for some nice defensive stocks to go along with the rest of your long positions in the portfolio, then take a look at the list of stocks below that are more defensive than growth oriented. They are stocks that...
-
Mylan Receives Approval for Generic Version of Effexor XR® Capsules
Thursday, June 2, 2011 - 12:01pm | 248Mylan (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Venlafaxine Hydrochloride Extended-release Capsules, 37.5 mg (base), 75 mg (base) and 150 mg...
-
Options Brief: Eli Lilly and Company
Thursday, June 2, 2011 - 10:27am | 77Shares of Eli Lilly and Company (NYSE: LLY) are lower on the session by 1.13%, trading at $37.51. Overall put volume is now running at 2.82x the daily average, with 12% of all puts traded being purchases on the offer. 17,151 contracts have traded on the session so far. Eli Lilly and Company...
-
Pfizer and Hisun Sign MOU to Increase Access to Quality and Low-Cost Medicines for Patients in China
Thursday, June 2, 2011 - 9:22am | 60Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals today jointly announced the signing of a memorandum of understanding on their intention to establish a joint venture. This potential partnership would aim to strengthen the ability of both companies to reach more patients with high-quality...
-
Daiwa Comments On Johnson & Johnson Product Plan
Thursday, June 2, 2011 - 8:34am | 100According to Daiwa Capital Markets, Johnson & Johnson (NYSE: JNJ) updated investors on its Pharmaceutical new product plan. Daiwa said that it rates JNJ 2. “We expect drug sales to be up 10.3% this year and 8.2% in 2012, driven by recently introduced drugs and by products currently in the...
-
Benzinga's Top Upgrades
Thursday, June 2, 2011 - 8:09am | 135Robert W. Baird upgraded Affymetrix Inc (NASDAQ: AFFX) from “neutral” to “outperform.” AFFX's shares closed at $6.28 yesterday. Affymetrix's trailing-twelve-month revenue is $304.28 million. Analysts at Needham upgraded FSI International Inc (NASDAQ: FSII) from “hold” to “buy.” FSII's shares...
-
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Thursday, June 2, 2011 - 8:03am | 137Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on May 31, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 411,750 shares of common stock to 27 new employees. Each stock option has an exercise...
-
First Global Upgrades Johnson & Johnson To Moderate Outperform
Thursday, June 2, 2011 - 7:46am | 19First Global has upgraded Johnon & Johnson (NYSE: JNJ) to Moderate Outperform.
-
Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement to Conduct Combination Studies with YERVOY and Vemurafenib
Thursday, June 2, 2011 - 7:04am | 63Bristol-Myers Squibb Company (NYSE: BMY) announced today it has entered in to a clinical collaboration agreement with Roche (RHHBY) to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY, in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating...
-
GSK and Theravance Announce Results of Two Pivotal Phase III Studies for Relovair(TM) in COPD
Thursday, June 2, 2011 - 7:04am | 91GlaxoSmithKline (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the results of two pivotal 6-month efficacy and safety phase III studies of Relovair for patients with chronic obstructive pulmonary disease. Results of both studies support the continuation of the Relovair development...